DI-LEU16-IL2 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses DI-LEU16-IL2 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- DI-Leu16-IL2
- 2
Studies by the year they started
3 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Alopexx Oncology, LLC (2) · City of Hope Medical Center (1)
Studies
Open first, then newest update. How each study uses DI-LEU16-IL2 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaCompletedPhase 1City of Hope Medical CenterNCT00720135Written as DI-Leu16-IL2 immunocytokineHow we know
- Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHLTerminatedPhase 1/2Alopexx Oncology, LLCNCT02151903Written as DI-Leu16-IL2How we know
- A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHLTerminatedPhase 1/2Alopexx Oncology, LLCNCT01874288Written as DI-Leu16-IL2How we know
Codes
What other systems call DI-LEU16-IL2 · ClinicalTrials.gg INT015698
- UNII (FDA) 8PQK3QPW4PDI-LEU16-IL2One source FDA
- NCI Thesaurus C78451DI-Leu16-IL2 ImmunocytokineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8PQK3QPW4P | DI-LEU16-IL2 | One source FDA |
| NCI Thesaurus | C78451 | DI-Leu16-IL2 Immunocytokine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.